2024
CT for Congenital Heart Disease
Fuss C. CT for Congenital Heart Disease. 2024, 277-293. DOI: 10.1007/978-981-97-6919-3_21.Peer-Reviewed Original ResearchCongenital heart diseaseHeart diseaseEvaluation of congenital heart diseaseManagement of congenital heart diseaseContrast doseAffected patientsBirth defectsStages of repairRadiation exposureAltered physiologySmall organ sizeCT roleDiseaseVariable stagesCongenitallyPatientsCTDoseSpatial image resolutionComplexity of defectsBirth
2022
U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
Carpenter S, Chandler M, Guerrera M, Malec L, Manuel M, Recht M, Reiss U, Sidonio R, Tarango C, Van den Berg M, Wang M, Thornburg C. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics. Blood 2022, 140: 63-64. DOI: 10.1182/blood-2022-162660.Peer-Reviewed Original ResearchA Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors
Chrisentery-Singleton T, Amos L, Bonzo D, Escobar M, Giermasz A, Lagrue E, Knoll C, Nasr S, Recht M, Sullivan S, Quon D, Reding M. A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors. Blood 2022, 140: 11360-11361. DOI: 10.1182/blood-2022-163372.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply